Skip to main content
Erschienen in: Journal of Neurology 12/2023

14.08.2023 | Original Communication

Cognitive impairment and dementia in young onset Parkinson’s disease

verfasst von: Diego Santos-García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, María J. Feal Painceiras, Iago García Díaz, María Cristina Íñiguez Alvarado, Jose Manuel Paz, Silvia Jesús, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Julio Dotor García-Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Zebenzui Mendoza, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Manuel Seijo, Caridad Valero, Ruben Alonso Redondo, Maria Teresa Buongiorno, Carlos Ordás, Manuel Menéndez-González, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, COPPADIS Study Group

Erschienen in: Journal of Neurology | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Patients with young-onset Parkinson’s disease (YOPD) have a slower progression. Our aim was to analyze the change in cognitive function in YOPD compared to patients with a later onset and controls.

Patients and methods

Patients with Parkinson’s disease (PD) and controls from the COPPADIS cohort were included. Cognitive function was assessed with the Parkinson’s Disease Cognitive Rating Scale (PD-CRS) at baseline (V0), 2-year ± 1 month (V2y), and 4-year ± 3 months follow-up (V4y). Regarding age from symptoms onset, patients were classified as YOPD (< 50 years) or non-YOPD (≥ 50). A score in the PD-CRS < 81 was defined as cognitive impairment (CI): ≤ 64 dementia; 65–80 mild cognitive impairment (MCI).

Results

One-hundred and twenty-four YOPD (50.7 ± 7.9 years; 66.1% males), 234 non-YOPD (67.8 ± 7.8 years; 59.3% males) patients, and 205 controls (61 ± 8.3 years; 49.5% males) were included. The score on the PD-CRS and its subscore domains was higher at all visits in YOPD compared to non-YOPD patients and to controls (p < 0.0001 in all analysis), but no differences were detected between YOPD patients and controls. Only non-YOPD patients had significant impairment in their cognitive function from V0 to V4y (p < 0.0001). At V4y, the frequency of dementia and MCI was 5% and 10% in YOPD compared to 25.2% and 22.3% in non-YOPD patients (p < 0.0001). A lower score on the Parkinson’s Disease Sleep Scale at baseline was a predictor of CI at V4y in YOPD patients (Adjusted R2 = 0.61; OR = 0.965; p = 0.029).

Conclusion

Cognitive dysfunction progressed more slowly in YOPD than in non-YOPD patients.
Literatur
1.
Zurück zum Zitat Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49:328–338PubMedCrossRef Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49:328–338PubMedCrossRef
2.
Zurück zum Zitat Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR (2017) Parkinson’s: a syndrome rather than a disease? J Neural Transm (Vienna) 124:907–914PubMedCrossRef Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR (2017) Parkinson’s: a syndrome rather than a disease? J Neural Transm (Vienna) 124:907–914PubMedCrossRef
3.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedPubMedCentralCrossRef Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601PubMedCrossRef Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601PubMedCrossRef
5.
Zurück zum Zitat Post B, van den Heuvel L, van Prooije T, van Ruissen X, van de Warrenburg B, Nonnekes J (2020) Young onset Parkinson’s disease: a modern and tailored approach. J Parkinsons Dis 10(s1):S29-36PubMedPubMedCentralCrossRef Post B, van den Heuvel L, van Prooije T, van Ruissen X, van de Warrenburg B, Nonnekes J (2020) Young onset Parkinson’s disease: a modern and tailored approach. J Parkinsons Dis 10(s1):S29-36PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Morales-Briceno H, Mohammad SS, Post B et al (2020) Clinical and neuroimaging phenotypes of genetic parkinsonism from infancy to adolescence. Brain 143:751–770PubMedCrossRef Morales-Briceno H, Mohammad SS, Post B et al (2020) Clinical and neuroimaging phenotypes of genetic parkinsonism from infancy to adolescence. Brain 143:751–770PubMedCrossRef
7.
Zurück zum Zitat Mehanna R, Jankovic J (2019) Young-onset Parkinson’s disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord 65:39–48PubMedCrossRef Mehanna R, Jankovic J (2019) Young-onset Parkinson’s disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord 65:39–48PubMedCrossRef
8.
Zurück zum Zitat Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG (1993) Environmental antecedents of young-onset Parkinson’s disease. Neurology 43:1150–1158PubMedCrossRef Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG (1993) Environmental antecedents of young-onset Parkinson’s disease. Neurology 43:1150–1158PubMedCrossRef
10.
Zurück zum Zitat Schrag A, Hovris A, Morley D, Quinn N, Jahanshahim M (2003) Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord 18:1250–1256PubMedCrossRef Schrag A, Hovris A, Morley D, Quinn N, Jahanshahim M (2003) Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord 18:1250–1256PubMedCrossRef
11.
Zurück zum Zitat Klepac N, Habek M, Adamec I et al (2013) An update on the management of young-onset Parkinson’s disease. Degener Neurol Neuromuscul Dis 2:53–62PubMedPubMedCentral Klepac N, Habek M, Adamec I et al (2013) An update on the management of young-onset Parkinson’s disease. Degener Neurol Neuromuscul Dis 2:53–62PubMedPubMedCentral
12.
Zurück zum Zitat Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson’s disease. Mov Disord 2:73–91PubMedCrossRef Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson’s disease. Mov Disord 2:73–91PubMedCrossRef
13.
Zurück zum Zitat Holden HM, Schweer CN, Tröster AI (2021) Impact of mild cognitive impairment on quality of life in young and typical onset Parkinson’s disease. Mov Disord Clin Pract 9:69–75PubMedPubMedCentralCrossRef Holden HM, Schweer CN, Tröster AI (2021) Impact of mild cognitive impairment on quality of life in young and typical onset Parkinson’s disease. Mov Disord Clin Pract 9:69–75PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Willis AW, Schootman M, Kung N, Racette BA (2013) Epidemiology and neuropsychiatric manifestations of young onset Parkinson’s disease in the United States. Parkinsonism Relat Disord 19:202–206PubMedCrossRef Willis AW, Schootman M, Kung N, Racette BA (2013) Epidemiology and neuropsychiatric manifestations of young onset Parkinson’s disease in the United States. Parkinsonism Relat Disord 19:202–206PubMedCrossRef
15.
Zurück zum Zitat Santos García D, Jesús S, Aguilar M et al (2019) COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015): an ongoing global Parkinson’s disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. Eur J Neurol 26:1399–1407PubMedCrossRef Santos García D, Jesús S, Aguilar M et al (2019) COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015): an ongoing global Parkinson’s disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. Eur J Neurol 26:1399–1407PubMedCrossRef
16.
Zurück zum Zitat Santos-García D, Mir P, Cubo E et al (2016) COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multi-center, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol 16:26PubMedPubMedCentralCrossRef Santos-García D, Mir P, Cubo E et al (2016) COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multi-center, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol 16:26PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Zhou Z, Zhou X, Xiang Y et al (2022) Subtyping of early-onset Parkinson’s disease using cluster analysis: a large cohort study. Front Aging Neurosci 14:1040293PubMedPubMedCentralCrossRef Zhou Z, Zhou X, Xiang Y et al (2022) Subtyping of early-onset Parkinson’s disease using cluster analysis: a large cohort study. Front Aging Neurosci 14:1040293PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Zhao Y, Qin L, Pan H et al (2020) The role of genetics in Parkinson’s disease: a large cohort study in Chinese mainland population. Brain 143:2220–2234PubMedCrossRef Zhao Y, Qin L, Pan H et al (2020) The role of genetics in Parkinson’s disease: a large cohort study in Chinese mainland population. Brain 143:2220–2234PubMedCrossRef
19.
Zurück zum Zitat Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 23(3):17013CrossRef Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 23(3):17013CrossRef
20.
Zurück zum Zitat Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A (2008) Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 23:998–1005PubMedCrossRef Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A (2008) Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 23:998–1005PubMedCrossRef
21.
Zurück zum Zitat Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Pascual-Sedano B, Campolongo A, Kulisevsky J (2013) Parkinson’s disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord 28:1376–1383PubMedCrossRef Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Pascual-Sedano B, Campolongo A, Kulisevsky J (2013) Parkinson’s disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord 28:1376–1383PubMedCrossRef
22.
Zurück zum Zitat Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and Safinamide. Mov Disord Clin Pract 7:343–345PubMedPubMedCentralCrossRef Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and Safinamide. Mov Disord Clin Pract 7:343–345PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132(Pt 11):2947–2957PubMedCrossRef Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132(Pt 11):2947–2957PubMedCrossRef
24.
Zurück zum Zitat Ferguson LW, Rajput AH, Rajput A (2016) Early-onset vs. late-onset Parkinson’s disease: a clinical-pathological study. Can J Neurol Sci 43:113–119PubMedCrossRef Ferguson LW, Rajput AH, Rajput A (2016) Early-onset vs. late-onset Parkinson’s disease: a clinical-pathological study. Can J Neurol Sci 43:113–119PubMedCrossRef
25.
Zurück zum Zitat Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5:355–363PubMedCrossRef Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5:355–363PubMedCrossRef
26.
Zurück zum Zitat Wickremaratchi MM, Ben-Shlomo Y, Morris HR (2009) The effect of onset age on the clinical features of Parkinson’s disease. Eur J Neurol 16:450–456PubMedCrossRef Wickremaratchi MM, Ben-Shlomo Y, Morris HR (2009) The effect of onset age on the clinical features of Parkinson’s disease. Eur J Neurol 16:450–456PubMedCrossRef
27.
Zurück zum Zitat Lawson RA, Yarnall AJ, Duncan GW et al (2014) Severity of mild cognitive impairment in early Parkinson’s disease contributes to poorer quality of life. Parkinsonism Relat Disord 20:1071–1075PubMedPubMedCentralCrossRef Lawson RA, Yarnall AJ, Duncan GW et al (2014) Severity of mild cognitive impairment in early Parkinson’s disease contributes to poorer quality of life. Parkinsonism Relat Disord 20:1071–1075PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Tang H, Huang J, Nie K et al (2016) Cognitive profile of Parkinson’s disease patients: a comparative study between early-onset and late-onset Parkinson’s disease. Int J Neurosci 126:227–234PubMedCrossRef Tang H, Huang J, Nie K et al (2016) Cognitive profile of Parkinson’s disease patients: a comparative study between early-onset and late-onset Parkinson’s disease. Int J Neurosci 126:227–234PubMedCrossRef
29.
Zurück zum Zitat Mayeux R, Denaro J, Hemenegildo N et al (1992) A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 49:492–497PubMedCrossRef Mayeux R, Denaro J, Hemenegildo N et al (1992) A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 49:492–497PubMedCrossRef
30.
31.
32.
33.
Zurück zum Zitat Matsumoto S, Tsunematsu T (2021) Association between Sleep, Alzheimer’s, and Parkinson’s disease. Biology (Basel) 10:1127PubMed Matsumoto S, Tsunematsu T (2021) Association between Sleep, Alzheimer’s, and Parkinson’s disease. Biology (Basel) 10:1127PubMed
35.
Zurück zum Zitat Leocadi M, Canu E, Donzuso G et al (2022) Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson’s disease patients. J Neurol 269:1485–1500PubMedCrossRef Leocadi M, Canu E, Donzuso G et al (2022) Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson’s disease patients. J Neurol 269:1485–1500PubMedCrossRef
36.
Zurück zum Zitat Santos García D, de Deus Fonticoba T, Suárez Castro E et al (2019) Coppadis Study Group. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson’s disease patients: results from the COPPADIS Study Cohort. Parkinsonism Relat Disord 66:151–157PubMedCrossRef Santos García D, de Deus Fonticoba T, Suárez Castro E et al (2019) Coppadis Study Group. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson’s disease patients: results from the COPPADIS Study Cohort. Parkinsonism Relat Disord 66:151–157PubMedCrossRef
37.
Zurück zum Zitat Spica V, Pekmezović T, Svetel M, Kostić VS (2013) Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s disease. J Neurol 260:131–137PubMedCrossRef Spica V, Pekmezović T, Svetel M, Kostić VS (2013) Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s disease. J Neurol 260:131–137PubMedCrossRef
38.
Zurück zum Zitat Kim R, Shin JH, Park S, Kim HJ, Jeon B (2020) Longitudinal evolution of non-motor symptoms according to age at onset in early Parkinson’s disease. J Neurol Sci 418:117157PubMedCrossRef Kim R, Shin JH, Park S, Kim HJ, Jeon B (2020) Longitudinal evolution of non-motor symptoms according to age at onset in early Parkinson’s disease. J Neurol Sci 418:117157PubMedCrossRef
39.
Zurück zum Zitat Vela L, Martínez Castrillo JC, García Ruiz P et al (2016) The high prevalence of impulse control behaviors in patients with early-onset Parkinson’s disease: a cross-sectional multi-center study. J Neurol Sci 368:150–154PubMedCrossRef Vela L, Martínez Castrillo JC, García Ruiz P et al (2016) The high prevalence of impulse control behaviors in patients with early-onset Parkinson’s disease: a cross-sectional multi-center study. J Neurol Sci 368:150–154PubMedCrossRef
40.
Zurück zum Zitat Kelly MJ, Lawton MA, Baig F et al (2019) Predictors of motor complications in early Parkinson’s disease: a prospective cohort study. Mov Disord 34:1174–1183PubMedPubMedCentralCrossRef Kelly MJ, Lawton MA, Baig F et al (2019) Predictors of motor complications in early Parkinson’s disease: a prospective cohort study. Mov Disord 34:1174–1183PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Te Groen M, Bloem BR, Wu SS, Post B (2021) Parkinson’s Foundation Quality Improvement Initiative investigators. Better quality of life and less caregiver strain in young-onset Parkinson’s disease: a multicentre retrospective cohort study. J Neurol 268:1102–1109CrossRef Te Groen M, Bloem BR, Wu SS, Post B (2021) Parkinson’s Foundation Quality Improvement Initiative investigators. Better quality of life and less caregiver strain in young-onset Parkinson’s disease: a multicentre retrospective cohort study. J Neurol 268:1102–1109CrossRef
42.
Zurück zum Zitat Knipe MD, Wickremaratchi MM, Wyatt-Haines E, Morris HR, Ben-Shlomo Y (2011) Quality of life in young- compared with late-onset Parkinson’s disease. Mov Disord 26:2011–2018PubMedCrossRef Knipe MD, Wickremaratchi MM, Wyatt-Haines E, Morris HR, Ben-Shlomo Y (2011) Quality of life in young- compared with late-onset Parkinson’s disease. Mov Disord 26:2011–2018PubMedCrossRef
43.
Zurück zum Zitat Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118PubMedCrossRef Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118PubMedCrossRef
44.
Zurück zum Zitat Lawton M, Ben-Shlomo Y, May MT et al (2018) Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry 89:1279–1287PubMedCrossRef Lawton M, Ben-Shlomo Y, May MT et al (2018) Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry 89:1279–1287PubMedCrossRef
45.
Zurück zum Zitat Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB (2015) New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72:863–873PubMedCrossRef Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB (2015) New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72:863–873PubMedCrossRef
46.
Zurück zum Zitat Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324PubMedCrossRef Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324PubMedCrossRef
Metadaten
Titel
Cognitive impairment and dementia in young onset Parkinson’s disease
verfasst von
Diego Santos-García
Teresa de Deus Fonticoba
Carlos Cores Bartolomé
María J. Feal Painceiras
Iago García Díaz
María Cristina Íñiguez Alvarado
Jose Manuel Paz
Silvia Jesús
Marina Cosgaya
Juan García Caldentey
Nuria Caballol
Ines Legarda
Jorge Hernández Vara
Iria Cabo
Lydia López Manzanares
Isabel González Aramburu
Maria A. Ávila Rivera
Víctor Gómez Mayordomo
Víctor Nogueira
Julio Dotor García-Soto
Carmen Borrué
Berta Solano Vila
María Álvarez Sauco
Lydia Vela
Sonia Escalante
Esther Cubo
Zebenzui Mendoza
Juan C. Martínez Castrillo
Pilar Sánchez Alonso
Maria G. Alonso Losada
Nuria López Ariztegui
Itziar Gastón
Jaime Kulisevsky
Manuel Seijo
Caridad Valero
Ruben Alonso Redondo
Maria Teresa Buongiorno
Carlos Ordás
Manuel Menéndez-González
Darrian McAfee
Pablo Martinez-Martin
Pablo Mir
COPPADIS Study Group
Publikationsdatum
14.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 12/2023
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-023-11921-w

Weitere Artikel der Ausgabe 12/2023

Journal of Neurology 12/2023 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.